Elhai, Muriel http://orcid.org/0000-0001-8627-5758
Micheroli, Raphael http://orcid.org/0000-0002-8918-7304
Houtman, Miranda
Mirrahimi, Masoumeh
Moser, Larissa
Pauli, Chantal
Bürki, Kristina
Laimbacher, Andrea
Kania, Gabriela http://orcid.org/0000-0003-3788-4594
Klein, Kerstin http://orcid.org/0000-0001-5303-8027
Schätzle, Philipp
Frank Bertoncelj, Mojca
Edalat, Sam G.
Keusch, Leandra
Khmelevskaya, Alexandra
Toitou, Melpomeni http://orcid.org/0000-0002-4402-304X
Geiss, Celina http://orcid.org/0000-0002-8740-706X
Rauer, Thomas http://orcid.org/0000-0003-4775-1103
Sakkou, Maria
Kollias, George http://orcid.org/0000-0003-1867-3150
Armaka, Marietta http://orcid.org/0000-0003-0985-9076
Distler, Oliver http://orcid.org/0000-0002-0546-8310
Ospelt, Caroline http://orcid.org/0000-0002-9151-4650
Article History
Received: 2 February 2023
Accepted: 28 November 2023
First Online: 9 December 2023
Change Date: 29 April 2024
Change Type: Update
Change Details: In the original version of this article, the given and family names of Mojca Frank Bertoncelj were incorrectly structured. The name was displayed correctly in all versions at the time of publication. The original article has been corrected.
Competing interests
: M.E., R.M., L.K., A.K., M.T., T.R., C.G., M.H., M.M., L.M., C.P., K.B., A.L., G.K., K.K., P.S., M.F.B., S.G.E., M.S., G.K., M.A., and C.O. declare no competing interests. O.D. has/had relationships with the following companies in the area of potential treatments for systemic sclerosis and its complications in the last three calendar years: Speaker fee: Bayer, Boehringer Ingelheim, Janssen, Medscape Consultancy fee: 4P-Pharma, Abbvie, Acceleron, Alcimed, Altavant Siences, Amgen, AnaMar, Arxx, AstraZeneca, Baecon, Blade, Bayer, Boehringer Ingelheim, Corbus, CSL Behring, Galapagos, Glenmark, Horizon, Inventiva, Kymera, Lupin, Miltenyi Biotec, Mitsubishi Tanabe, MSD, Novartis, Prometheus, Redxpharna, Roivant, Sanofi and Topadur Research Grants: Kymera, Mitsubishi Tanabe, Boehringer Ingelheim Oliver Distler has/had relationships with the following companies in the area of potential treatments for dermatomyositis and its complications in the last three calendar years: Consultancy fee for rheumatology topic: Pfizer (2021) Oliver Distler has/had relationships with the following companies in the area of potential treatments for arthritides in the last three Consultancy fee: Abbvie.